Synaptogenix Inc (SNPX)

[DRK123]

From my understanding, they are Not Considered Liabilities. In fact they may be deemed superior long-term investment strategies for the holder. If exercised at the strike price there is dilution, but there is also capital raised for the company, which is the trade off.

And there is a strong probability of NTRP’s share price reaching its 2017, $29/share price, which would make most of us millionaires. If the Alzheimer’s sector is a multi-billion $ segment in healthcare, and if this new long-term (6 month) trial is successful, the share price could reach $79/share easily

3 billion divide by 38 million (38 million representing double the public float)